Directors report continued Share issuance Equity At the AGM on 12 May 2016, the Directors were Capital structure authorised to issue relevant securities up to an aggregate nominal amount of 7,979,517 and to be empowered to Details of the issued share capital, together with allot equity securities for cash on a non pre-emptive basis movements in the issued share capital during the year, up to an aggregate nominal amount of 2,393,855at can be found in Note 33 to the financial statements.
any time up to the earlier of the date of the 2017 AGM Hikma has one class of ordinary shares of 10 pence each or 30 June 2017.
The Directors propose to renew these Shares which carries no right to fixed income.
Each authorities at the 2017 AGM for a further year.
In the share carries the right to one vote at general meetings year ahead, other than in respect of Hikmas obligations of Hikma.
As at 31 December 2016: to satisfy rights granted to employees under its various Issued during share-based incentive arrangements, the Directors have Type Nominal value In issue the year no present intention of issuing any additional share capital Ordinary 10 pence 239,954,532 40,569,414 of Hikma.
On 29 February 2016, the Company issued 40,000,000 Details of the employee share schemes are set out in Note ordinary shares to Boehringer Ingelheim pursuant to the 38 to the financial statements.
Shares are also held by the acquisition of Roxane Laboratories that was approved Hikma Pharmaceuticals Employee Benefit Trust EBT by shareholders on 19 February 2016.
Otherwise, during and are detailed in Note 35 to the financial statements.
The 2016, Hikma issued ordinary shares solely pursuant to the EBT has waived its right to vote on the Shares it holds and exercise of options under the 2004 Stock Option Plan, also to its entitlement to a dividend.
No other shareholder 2005 Long Term Incentive Plan, 2009 Management has waived the right to a dividend.
Incentive Plan and 2014 Executive Incentive Plan.
There are no specific restrictions on the size of a holding Annual General Meeting or on the transfer of Shares, which are both governed by The AGM of Hikma will be held at Sofitel St James, the general provisions of Hikmas Articles of Association 6 Waterloo Place, London SW1Y 4AN on Friday, the Articles and prevailing legislation.
Other than the 19 May 2017, starting at 10.00 a. m. The Notice shareholder agreement between Boehringer Ingelheim convening the meeting is given in a separate document BI and Hikma the Agreement, the Directors are accompanying this document, and includes a commentary not aware of any agreements between holders of Hikmas on the business of the AGM, and notes to help Shares that may have resulted in restrictions on the transfer shareholders exercise their rights at the meeting.
of securities or on voting rights.
The Agreement restricts The Company provides for the vote on each resolution BIs voting rights to 28,500,000 Shares and the onward to be by poll rather than by show of hands.
This provides transfer of Shares until 1 January 2018, as disclosed in the for greater transparency and allows the votes of all combined Prospectus and Circular posted to shareholders shareholders to be counted, including those cast by proxy.
No person has any special rights with The level of proxies lodged for each resolution is projected regard to the control of Hikmas share capital and all onto a screen as each resolution is put to the meeting.
A issued Shares are fully paid.
Hikma has not placed any vote withheld explanation is included on the proxy cards.
Shares into treasury during the period under review.
The powers of the Directors are determined by the Share buy-back Articles, the UK Code and other relevant UK legislation.
The Articles give the Directors the power to appoint At the AGM on 12 May 2016, shareholders gave the and remove Directors.
The power to issue and allot Shares Directors authority to purchase Shares from the market contained in the Articles is subject to shareholder approval up to an amount equal to 10% of Hikmas issued share at each AGM.
The Articles, which are available on the capital at that time.
This authority expires at the earlier of website, may only be amended by special resolution 30 June 2017 or the 2017 AGM, which is scheduled for of the shareholders.
The Directors have not used this authority during the year, but are proposing to renew this authority at the 2017 AGM.
Additionally, at the Extraordinary General Meeting held on 19 February 2016, shareholders gave the Directors authority to re-purchase Shares from Boehringer Ingelheim that were issued in respect of the Roxane acquisition.
This authority expires on 22 January 2021.
